* agilon health inc AGL.N AGL is expected to show a rise
in
quarterly revenue when it reports results on May 7 for the
period ending March 31 2024
* The Austin Texas-based company is expected to report a
41.1% increase in revenue to $1.604 billion from $1.14 billion a
year ago, according to the mean estimate from 16 analysts, based
on LSEG data.The company's guidance on February 27 2024, for the
period ended March 31, was for revenue between $1.61 billion and
$1.63 billion.
* LSEG's mean analyst estimate for agilon health inc is for
a
loss of 1 cent per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 12
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 12.6%
in the last three months.
* Wall Street's median 12-month price target for agilon
health inc
is $7.00, above its last closing price of $4.83.
The company's guidance on February 27 2024 for the period ended
March 31 was for Earnings before Interest, Taxes, Depreciation
and Amortization of between USD1.605 billion and USD25 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.32 -0.30 -0.41 Missed -36.3
Sep. 30 2023 -0.07 -0.06 -0.08 Missed -40.5
Jun. 30 2023 -0.03 -0.03 -0.04 Missed -57.5
Mar. 31 2023 0.02 0.02 0.04 Beat 83.3
Jan. -0.07 -0.09 -0.14 Missed -62.8
1 0001
Sep. 30 2022 -0.06 -0.05 -0.07 Missed -40
Jun. 30 2022 -0.02 -0.02 -0.05 Missed -177.8
Mar. 31 2022 0.00 0.00 0.00 Met -100
This summary was machine generated May 4 at 02:03 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)